Preliminary experience with inhaled nitric oxide for acute pulmonary hypertension after heart transplantation.
BACKGROUND
Substantial interest has developed in the physiologic and therapeutic role of nitric oxide in the last few years. In patients with pulmonary hypertension it appears to be a useful selective pulmonary vasodilator; however, many issues of both staff and patient safety remained unanswered.


METHODS
This study examines further safety issues and also presents preliminary clinical experience in patients after orthotopic heart transplantation with pulmonary hypertension and right-sided ventricular failure.


RESULTS
Atmospheric levels of nitric oxide and nitrogen dioxide are 100 times less than occupational health standards. When nitric oxide is used at 70 parts per million in the presence of a fraction of inspired oxygen greater than 0.60, nitrogen dioxide levels in the circuit exceed the published short-term exposure limit of the American Conference of Government Industrial Hygienist of 5 parts per million.


CONCLUSIONS
Staff safety appears confirmed, but despite encouraging clinical results, further longer term safety and efficacy studies are indicated.
Williams
T J
TJ
Department of Respiratory Medicine, Alfred Hospital, Melbourne, Australia.
Salamonsen
R F
RF
Snell
G
G
Kaye
D
D
Esmore
D S
DS
D000280:Administration, Inhalation; D016027:Heart Transplantation; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy*; D009569:Nitric Oxide / Q000008:administration & dosage* / Q000032:analysis / Q000633:toxicity; D009585:Nitrogen Dioxide / Q000032:analysis
D009569:Nitric Oxide; D009585:Nitrogen Dioxide